0731. Effects of sildenafil in a porcine model of endotoxemia
© Kemper et al; licensee Springer. 2014
Published: 26 September 2014
Sepsis-induced lung injury is one of the major causes of morbidity and mortality in intensive care patients . The clinical manifestations include pulmonary hypertension, formation of extravascular lung water (EVLW), and deterioration of pulmonary gas exchange. Administration of sildenafil, a selective inhibitor of isoenzyme phosphodiesterase-5, in patients with pulmonary hypertension improves oxygenation and ameliorates pulmonary hypertension .
To evaluate the effect of sildenafil on endotoxin-induced lung injury in pigs.
Twenty anesthetized and mechanically ventilated pigs were randomized after baseline (BL) measurements to Control (saline solution) or Sildenafil (100mg) group. After 30 minutes of saline/sildenafil administration, all animals were submitted to a continuous lipopolysaccharide (LPS) infusion (4mcg/kg/min) until the end of study. Hemodynamics and oxygenation parameters were evaluated at BL, 30, 60, 120 and 180 minutes after LPS (LPS60, LPS120 and LPS180). Plasma cytokines (TNF-alpha, IL-1beta, IL-6 and IL-10) were evaluated at BL and LPS180. The parametric data were analyzed using ANOVA for repeated measurements and nonparametric data with Kruskall-Wallis and the Mann-Whitney U test.
All cytokines increased after LPS infusion in both groups and no difference was observed between the animals receiving sildenafil and normal saline.
Sildenafil administration improved pulmonary hypertension and oxygenation in LPS-induced lung injury but increased shunt fraction and promoted systemic hypotension. It remains unclear whether sildenafil may be beneficial in sepsis patients.
Laboratory of Anesthesiology (LIM08), Faculdade de Medicina da Universidade de São Paulo.
- Rubenfeld GD, Caldwell E, Peabody E, et al.: Incidence and Outcomes of Acute Lung Injury. N Engl J Med 2005, 353: 1685–93. 10.1056/NEJMoa050333PubMedView ArticleGoogle Scholar
- Galie N, Ghofrani HA, Torbicki A, et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353: 2148–57. 10.1056/NEJMoa050010PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.